Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,124 people get NVS articles and Market Currents by email alert.
Get email alerts on NVS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
After AbbVie's Humira: What Next?Peter Geschek • Mon, May 6 -
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Novartis Moving Forward In GenericsPeter Pham • Mon, Dec 3, 2012 -
-
AHA - 2 Hits And Several Misses With Novartis' SerelaxinEP Vantage • Wed, Nov 7, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
After AbbVie's Humira: What Next?Peter Geschek • Mon, May 6
-
-
-
-
-
-
-
-
-
-
-
-
Novartis AG's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012 • 1 Comment
-
Novartis AG's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Jan 25, 2012
-
Novartis AG's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Oct 25, 2011
-
Novartis AG's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 19, 2011
-
Novartis CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Jan 27, 2011
-
Novartis 2009 Annual Conference Call TranscriptTue, Jan 26, 2010
-
Novartis AG Q3 2007 Earnings Call TranscriptThu, Oct 18, 2007 • 1 Comment
-
Novartis Q2 2007 Earnings Call TranscriptTue, Jul 17, 2007
-
at CNBC.com (Wed, 11:07AM)
-
at CNBC.com (May 10, 2013)
-
at Fox Business (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 8, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at Fox Business (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at CNBC.com (Feb 1, 2013)
-
at CNBC.com (Feb 1, 2013)
NVS vs. ETF Alternatives
Company Description
Currently, there's no company description for NVS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, October 24, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH 1 Comment [Earnings]
- Thursday, September 27, 2012, 8:19 AM Novartis' (NVS +1%) AIN457 treatment may significantly improve moderate-to-severe plaque psoriasis on the hands, feet and nails, Phase II data shows. Around 125M worldwide suffer from plaque psoriasis, a hard-to-treat chronic disease characterized by thick and extensive skin lesions that cause itching, scaling and pain. (PR) Comment! [Healthcare]
- Monday, September 24, 2012, 8:55 AM Novartis' (NVS +0.3%) RLX030 drug cut the number of deaths in patients with acute heart failure in a Phase III trial. (PR) Comment! [Healthcare]
- Tuesday, September 18, 2012, 6:45 PM The allure of dividend-paying stocks has not gone unnoticed by Morningstar's top managers, especially with bond yields at historically low levels and interest rates bound to go up over the next several years. The "ultimate stock pickers" tab these 10 high dividend yielders: VOD, GSK, COP, LLY, NVS, MRK, INTC, PFE, SYY, PM. 10 Comments [Quick Ideas]
- Wednesday, September 12, 2012, 7:18 PM Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis, making it the second oral therapy that will be available on the U.S. market. The drug will compete with Novartis' (NVS) Gilenya, an oral pill which was approved by the FDA in 2010. 1 Comment [Healthcare]
- Thursday, September 6, 2012, 8:57 AM An FDA advisory committee yesterday voted 13-1 to support the use of Novartis' (NVS +0.85%) tobramycin inhalation powder for patients with cystic fibrosis and whose lungs contain bacteria called Pseudomonas aeruginosa. The antibiotic powder would be more convenient than Novartis older version of tobramycin, which requires a nebulizer machine. Comment! [Healthcare]
- Wednesday, September 5, 2012, 10:09 AM The FDA's attempts to expedite drug approval may have undermined safety, an article in the Journal of the American Medical Association says. The authors, Thomas Moore and Curt Furberg, point to problems with Novartis' (NVS) Gilenya drug for multiple sclerosis, AstraZeneca's (AZN) Caprelsa for thyroid cancer and Boehringer Ingelheim's Pradaxa for stroke prevention. 2 Comments [Healthcare]
- Thursday, August 30, 2012, 8:30 AM Novartis (NVS) plans to file for Japanese and EU approval of QVA149 - a therapy that combines two of the company's other drugs and is used to treat smoker's cough - later this year after it met expectations in final trials. Yesterday, the FDA authorized a new dosage of Novartis' cancer drug Afinitor so it can be used to treat children with a rare brain tumor. (PR) Comment! [Healthcare]
- Monday, August 27, 2012, 12:14 PM Cell Therapeutics (CTIC +15.2%) jumps after announcing the licensing terms under which Novartis (NVS) would be able to develop and commercialize CTIC's Pixuvri cancer drug, which was recently approved by the EU. Should Novartis exercise its option on Pixuvri, the drug giant would owe CTIC a $7.5M license fee, up to $104M in milestone payments, and ongoing royalties. 3 Comments [Healthcare, On the Move]
- Sunday, August 26, 2012, 4:51 AM Novartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the organ's chambers are stiff but can still pump a reasonable amount of blood, performed well in a mid-stage trial. LCZ696 reduced levels of NT-proBNP, a protein that's linked to the condition. Larger studies are now needed to see whether this "biomarker" can lead to improved results in clinical practice. Comment! [Healthcare]
- Wednesday, August 22, 2012, 8:05 AM India's Supreme Court has postponed until Sept. 11 a crucial hearing over whether to grant patent protection to Novartis' (NVS) leading cancer drug Glivec, which the Indian government declined to provide. The hearing was due to take place today. The decision could affect how Big Pharma operates in India, and curb the country's leading position as a supplier of cut-price generic medicines. (previous) Comment! [Healthcare]
- Monday, August 20, 2012, 4:29 AM Novartis (NVS) is due to appear before India's Supreme Court on Wednesday in an attempt to gain patent protection for its leading cancer-drug Glivec, which the Indian government declined to provide. The case comes as India, although suffering from a slowing economy and high inflation, becomes increasingly unpredictable and unfriendly for foreign companies. Comment! [Healthcare, Global & FX]
- Tuesday, August 7, 2012, 9:49 AM More on Zalicus (ZLCS +6.25%) Q2: company has again extended its partnership with Novartis (NVS), "validating the value" of Zalicus' cHTS technology for developing cancer treatments. Zalicus is also on track to start Phase 2a trials of Z160, a drug for neuropathic pain, and to report results of a Phase IIb trial for Synavive, which is used for rheumatoid arthritis. (PR) Comment! [On the Move, Healthcare]
- Wednesday, August 1, 2012, 9:25 AM Idenix (IDIX) -6% to $9.52 after launching a $150M offering of common stock, a day after saying that it's revising its partnership agreement with Novartis (NVS). This includes Idenix no longer receiving royalty or milestone payments from the Swiss firm for hepatitis B drug Tyzeka. (PR) Comment! [Healthcare, On the Move]
- Monday, July 30, 2012, 9:59 AM EU regulators OK Novartis' (NVS -1%) Afinitor drug for treating women with a certain type of breast cancer. The latest approval adds to backing from the FDA for breast cancer, and to authorization for four other types of the disease. Kepler Capital Markets analyst Martin Voegtli reckons Afinitor is on course to be a blockbuster by next year. Comment! [Healthcare]
- Monday, July 23, 2012, 12:46 PM Bloomberg profiles Novartis' (NVS -0.6%) Afinitor drug, which received FDA approval on Friday for use in breast cancer. The treatment, which was already authorized for kidney tumors and organ transplant patients, generated sales of $318M in H1; sales could rise to $2.5B by 2016, forecasts Deutsche Bank's Tim Race. Comment! [Healthcare]
-
The Wall Street Transcript
Pets and Vets: Investment Returns from our Animal Companions: Part 2 - http://su.pr/1XyqiB $PFE, $SNY, $MRK, $NVS, $LLY, $MS - View all 0 replies
-
The Wall Street Transcript
Pets and Vets: Investment Returns from our Animal Companions- Part I- http://su.pr/8iJ2o4 $PFE, $MRK, $LLY, $NVS, $TGT, $WMT, $COST, $PETS - View all 0 replies
-
- View all 14 replies
-
-
-
The Wall Street Transcript
Investing in MLPs & Dividend Growth; Manager discusses $ADP, $IBM, $ITW, $MCD, $NESN.VX, $NVO, $NVS, $TEVA, $WAG- http://su.pr/2SbdfP - View all 0 replies
-
- View all 1 replies
-
-
- View all 3 replies
-
Ocean Man: Canadian but do most of their business in the US. Doubled their size a few months ago with an acquisition, said was immediately accretive.
-
neobliviscar: Heck of a yield. Need to sic our balance sheet terrier on it as soon as I can get her to look at it. I wish options mrkt on it was bigger.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES